内容概要：近年来，我国人口老龄化日益加剧，老年群体对于术后康复、慢性病治疗等方面的需求持续 增长，中频治疗仪在上述领域疗效显著，且随着康复医学的普及，骨科、神经科、产后康复等专科对中 频治疗仪的依赖度不断提升，此外，随着国民健康意识的不断增强，越来越多家庭会购置操作简便的中 频治疗仪用于日常疼痛缓解、亚健康调理等，带动我国中频治疗仪市场需求进一步增长，据比地招标网 数据显示，2024年我国中频治疗仪采购总量达6745台，同比增长37.26%；采购总金额达0.76亿元，同比 增长1.33%， 采购均价为1.13万元/台；2025年上半年我国中频治疗仪采购总量已完成2352台，采购总金 额已完成0.28亿元，其中，华南地区占比最大，高达30.47%，其次为华北地区和华东地区，分别占 20.14%和17.94%。 上市企业：翔宇医疗（688626）、倍益康（920199） 相关企业：宁波迈达医疗仪器有限公司、苏州好博医疗器械股份有限公司、三合正德（辽宁）医疗科技 有限公司、津准（三明）医学技术有限公司、中山市健怡康智能电子有限公司、郑州雅晨生物科技有限 公司、郑州名泰医疗器械有限公司、郑州静美医疗设备科技有限公司、 ...

Core Viewpoint - The company is focusing on expanding its production capacity and product line through innovation and strategic investments, particularly in the rehabilitation medical device sector [1][2][4]. Group 1: Investment and Expansion - The company is investing 400 million yuan in a new smart manufacturing base in Chengdu, expected to be completed by August this year, aimed at increasing production capacity and improving efficiency [1]. - The company has obtained 19 medical device registration certificates, covering various fields such as electrotherapy, oxygen therapy, and biofeedback [2]. Group 2: Product Development and Innovation - The company has launched several new products this year, including mid-frequency therapy devices and pelvic floor rehabilitation devices, which are essential for expanding market reach [1][2]. - The interference electric therapy device, a key product, has been developed with proprietary technology and patents, enhancing the company's competitiveness in the electrotherapy market [1]. - The company is also focusing on consumer health products, leveraging its expertise in professional medical devices to create innovative solutions for home use [3]. Group 3: Market Strategy - The company is actively expanding its overseas market presence, with products already reaching 70 countries, and plans to enhance its export efforts [4]. - The company recognizes the growing demand from the elderly population and is developing products tailored to their rehabilitation and health needs, such as portable oxygen machines and mid-frequency therapy devices [4].

Group 1: Investor Relations Activities - The company conducted a specific investor survey and media interviews on May 29, 2025, attended by representatives from Galaxy Securities, Rongxian Huijin Fund, and China Securities Journal [3][4] Group 2: Sales and Market Performance - The overseas market sales have remained stable this year, with the portable pneumatic massage system receiving widespread attention and positive feedback from global customers [4] - The company plans to enhance the market promotion of the compression boots, leveraging existing sales channels in the massage gun sector [4] Group 3: Product Innovation and Development - Future product innovation strategies include increased investment in "medical + consumer" resources and a focus on rehabilitation medical technology [5] - The company aims to develop more products suitable for the elderly, addressing the growing health needs of this demographic [5] Group 4: Profitability and Product Structure - The gross margin for rehabilitation medical products is 47.86%, while rehabilitation technology products have a gross margin of 37.11%, indicating room for improvement [6] - The company is actively developing new products to enrich its product line [6] Group 5: Investment Projects and Production Capacity - The Chengdu Intelligent Manufacturing Production Base is on track for completion, expected to be accepted in July 2025, which will enhance production capacity and efficiency [7] - The introduction of advanced production equipment and automated lines will lower production costs and improve overall profitability [7] Group 6: Research and Development - R&D expenses are determined by various factors, including company strategy and market demand, rather than a fixed threshold [9] - New products such as the medium-frequency therapy device and portable oxygen machine have received regulatory approval, while others are in development [9]